Eli Lilly will provide the US government with vials of its COVID-19 antibody therapy bamlanivimab (LY-CoV555) if the treatment is granted Emergency Use Authorisation.
List view / Grid view
Filter the results
Sanofi and GSK have agreed to support the COVID-19 vaccine (COVAX) Facility with 200 million doses of their adjuvanted, recombinant protein-based COVID-19 vaccine.
Charles River provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions around the globe accelerate their research and drug development efforts.
Integration of Movilitas.Cloud and NiceLabel simplifies serialised label printing for highly regulated industries
Centralised cloud-based solution delivers serialised label management that improves label quality assurance, minimises operational costs and manages product serialisation.
Clinical trials for AZD1222, the AstraZeneca COVID-19 vaccine candidate, have resumed across the world after confirmation it is safe to do so.
The study will establish whether NOviricid can improve COVID-19 patient outcomes and survival in 840 recently diagnosed African American patients with comorbidities.
According to various associations, the UK could experience a high influx of counterfeit medicines if it leaves the EU without a deal.
Polyethylene-based tubes with high-density polyethylene flip-top caps that are fully recyclable have been developed for use in pharma.
A Phase I clinical trial of remestemcel-L delivered by an endoscope to patients with Crohn’s disease and ulcerative colitis has commenced.
Hosted online from 11 – 12 November, Chemspec Digital 2020 provides an interactive networking event for the fine and speciality chemicals community. From all over the world, industry experts will have the opportunity to meet, conduct business, discover innovative substances and learn about the latest trends and developments.
NICE has recommended pembrolizumab for the treatment of metastatic or unresectable recurrent head and neck squamous cell carcinoma (HNSCC).
The FDA has given marketing authorisation for Veklury (remdesivir) to treat COVID-19 patients requiring hospitalisation.
A study has shown that aspirin use was associated with a 47 percent decrease in the risk of dying in the hospital from COVID-19.
The first-in-human clinical trial of nanoformed piroxicam will begin in late 2020, with results expected by mid-2021.
A new report has shown that through the COVID-19 pandemic, the global nasal drug delivery technology market is predicted to increase.